Bibliography
- How Does SUTENT® Work? [Website]; Available from: http://www.sutent.com/RCC/rcc_how_sutent_works.aspx. [Cited 13 July 2010]
- Nexavar Full Prescribing Information. 2009 [ Cited 13 July 2010]
- Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009;56(6):959-71
- Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;12(2):125-34
- Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
- Novartis Pharmaceuticals Corp. Afinitor (sorafenib) Prescribing Information; 2009
- Kay A, Motzer RJ, Figlin RA. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC) [abstract 278]. Presented at ASCO Genitourinary Cancers Symposium; 2009
- Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
- Motzer RJ, Escudier B, Oudard S, Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
- Gu XS, Rosenbaum PR. Comparison of mutlivariate matching methods: structures, distances, and algorithms. J Comput Graph Stat 1993;2:405-20
- Casciano R, Malangone E, Sherman S, An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients [abstract 4611]. J Clin Oncol 2010;28:15s
- Di Lorenzo G, Carteni G, Autorino R, Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 2009;27(27):4469-74
- Beck SD, Patel MI, Snyder ME, Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004;11(1):71-7
- Ronnen EA, Kondagunta GV, Ishill N, Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006;107(11):2617-21
- Motzer RJ, Bacik J, Mariani T, Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20(9):2376-81
- Heng DYC. Bukowski, RM. Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma. Oncol Rev 2007;1(3):170-6
- Spruance SL, Reid JE, Grace M, Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004;48(8):2787-92
- Ljungberg B, Hanbury DC, Kuczyk MA, Renal cell carcinoma guideline. Eur Urol 2007;51(6):1502-10
- De Reijke TM, Bellmunt J, van Poppel H, EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45(5):765-73
- Bellmunt J, Calvo E, Castellano D, Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol 2009;63(Suppl 1):S1-13
- Nathan P, Wagstaff J, Porfiri E, UK guidelines for the systemic treatment of renal cell carcinoma. Br J Hosp Med (Lond) 2009;70(5):284-6
- NCCN. NCCN Clinical Practice Guidelines in Oncology™. Kidney Cancer. V.2.2010. NCCN 2009
- Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. Int J Technol Assess Health Care 2008;24(2):170-7
- Signorovitch J. Robust comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28(10):935-45
- Song F, Harvey I, Lilford R. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epidemiol 2008;61(5):455-63
- Motzer RJ, Mazumbar M, Bacik J, Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530-40